Literature DB >> 1683920

First-pass metabolism of cyclosporin by the gut.

J C Kolars1, W M Awni, R M Merion, P B Watkins.   

Abstract

Cyclosporin is thought to be exclusively metabolised in the liver. We instilled cyclosporin into the small bowel of 2 patients during the anhepatic phase of liver transplantation; cyclosporin metabolites were readily detected in portal venous blood. Our findings indicate that the small intestine is a major site of cyclosporin breakdown: such intestinal metabolism might help to explain the poor oral bioavailability and drug interactions of cyclosporin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683920     DOI: 10.1016/0140-6736(91)92302-i

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  84 in total

1.  Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.

Authors:  S Kanamitsu; K Ito; C E Green; C A Tyson; N Shimada; Y Sugiyama
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

Review 2.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Authors:  Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 4.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

5.  Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.

Authors:  K Ito; H Kusuhara; Y Sugiyama
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

6.  Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.

Authors:  S D Raeissi; Z Guo; G L Dobson; P Artursson; I J Hidalgo
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 7.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 8.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 9.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

10.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.